The Effects of Opioids on HIV Neuropathogenesis

Aniella Murphy, John Barbaro, Pablo Martínez-Aguado, Vanessa Chilunda, Matias Jaureguiberry-Bravo, Joan W. Berman

Research output: Contribution to journalReview article

Abstract

HIV associated neurocognitive disorders (HAND) are a group of neurological deficits that affect approximately half of people living with HIV (PLWH) despite effective antiretroviral therapy (ART). There are currently no reliable molecular biomarkers or treatments for HAND. Given the national opioid epidemic, as well as illegal and prescription use of opioid drugs among PLWH, it is critical to characterize the molecular interactions between HIV and opioids in cells of the CNS. It is also important to study the role of opioid substitution therapies in the context of HIV and CNS damage in vitro and in vivo. A major mechanism contributing to HIV neuropathogenesis is chronic, low-level inflammation in the CNS. HIV enters the brain within 4–8 days after peripheral infection and establishes CNS reservoirs, even in the context of ART, that are difficult to identify and eliminate. Infected cells, including monocytes, macrophages, and microglia, produce chemokines, cytokines, neurotoxic mediators, and viral proteins that contribute to chronic inflammation and ongoing neuronal damage. Opioids have been shown to impact these immune cells through a variety of molecular mechanisms, including opioid receptor binding and cross desensitization with chemokine receptors. The effects of opioid use on cognitive outcomes in individuals with HAND in clinical studies is variable, and thus multiple biological mechanisms are likely to contribute to the complex relationship between opioids and HIV in the CNS. In this review, we will examine what is known about both HIV and opioid mediated neuropathogenesis, and discuss key molecular processes that may be impacted by HIV and opioids in the context of neuroinflammation and CNS damage. We will also assess what is known about the effects of ART on these processes, and highlight areas of study that should be addressed in the context of ART.

Original languageEnglish (US)
Article number2445
JournalFrontiers in immunology
Volume10
DOIs
StatePublished - Oct 18 2019

Fingerprint

Opioid Analgesics
HIV
Opiate Substitution Treatment
Inflammation
Therapeutics
Chemokine Receptors
Microglia
Opioid Receptors
Viral Proteins
Chemokines
Prescriptions
Monocytes
Biomarkers
Macrophages
Cytokines

Keywords

  • buprenorphine
  • central nervous system
  • HIV-associated neurocognitive disorders
  • macrophages
  • monocytes
  • next generation sequencing
  • substance abuse

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Murphy, A., Barbaro, J., Martínez-Aguado, P., Chilunda, V., Jaureguiberry-Bravo, M., & Berman, J. W. (2019). The Effects of Opioids on HIV Neuropathogenesis. Frontiers in immunology, 10, [2445]. https://doi.org/10.3389/fimmu.2019.02445

The Effects of Opioids on HIV Neuropathogenesis. / Murphy, Aniella; Barbaro, John; Martínez-Aguado, Pablo; Chilunda, Vanessa; Jaureguiberry-Bravo, Matias; Berman, Joan W.

In: Frontiers in immunology, Vol. 10, 2445, 18.10.2019.

Research output: Contribution to journalReview article

Murphy, A, Barbaro, J, Martínez-Aguado, P, Chilunda, V, Jaureguiberry-Bravo, M & Berman, JW 2019, 'The Effects of Opioids on HIV Neuropathogenesis', Frontiers in immunology, vol. 10, 2445. https://doi.org/10.3389/fimmu.2019.02445
Murphy A, Barbaro J, Martínez-Aguado P, Chilunda V, Jaureguiberry-Bravo M, Berman JW. The Effects of Opioids on HIV Neuropathogenesis. Frontiers in immunology. 2019 Oct 18;10. 2445. https://doi.org/10.3389/fimmu.2019.02445
Murphy, Aniella ; Barbaro, John ; Martínez-Aguado, Pablo ; Chilunda, Vanessa ; Jaureguiberry-Bravo, Matias ; Berman, Joan W. / The Effects of Opioids on HIV Neuropathogenesis. In: Frontiers in immunology. 2019 ; Vol. 10.
@article{2030d67d978a440e970e81b1c2cfe57d,
title = "The Effects of Opioids on HIV Neuropathogenesis",
abstract = "HIV associated neurocognitive disorders (HAND) are a group of neurological deficits that affect approximately half of people living with HIV (PLWH) despite effective antiretroviral therapy (ART). There are currently no reliable molecular biomarkers or treatments for HAND. Given the national opioid epidemic, as well as illegal and prescription use of opioid drugs among PLWH, it is critical to characterize the molecular interactions between HIV and opioids in cells of the CNS. It is also important to study the role of opioid substitution therapies in the context of HIV and CNS damage in vitro and in vivo. A major mechanism contributing to HIV neuropathogenesis is chronic, low-level inflammation in the CNS. HIV enters the brain within 4–8 days after peripheral infection and establishes CNS reservoirs, even in the context of ART, that are difficult to identify and eliminate. Infected cells, including monocytes, macrophages, and microglia, produce chemokines, cytokines, neurotoxic mediators, and viral proteins that contribute to chronic inflammation and ongoing neuronal damage. Opioids have been shown to impact these immune cells through a variety of molecular mechanisms, including opioid receptor binding and cross desensitization with chemokine receptors. The effects of opioid use on cognitive outcomes in individuals with HAND in clinical studies is variable, and thus multiple biological mechanisms are likely to contribute to the complex relationship between opioids and HIV in the CNS. In this review, we will examine what is known about both HIV and opioid mediated neuropathogenesis, and discuss key molecular processes that may be impacted by HIV and opioids in the context of neuroinflammation and CNS damage. We will also assess what is known about the effects of ART on these processes, and highlight areas of study that should be addressed in the context of ART.",
keywords = "buprenorphine, central nervous system, HIV-associated neurocognitive disorders, macrophages, monocytes, next generation sequencing, substance abuse",
author = "Aniella Murphy and John Barbaro and Pablo Mart{\'i}nez-Aguado and Vanessa Chilunda and Matias Jaureguiberry-Bravo and Berman, {Joan W.}",
year = "2019",
month = "10",
day = "18",
doi = "10.3389/fimmu.2019.02445",
language = "English (US)",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The Effects of Opioids on HIV Neuropathogenesis

AU - Murphy, Aniella

AU - Barbaro, John

AU - Martínez-Aguado, Pablo

AU - Chilunda, Vanessa

AU - Jaureguiberry-Bravo, Matias

AU - Berman, Joan W.

PY - 2019/10/18

Y1 - 2019/10/18

N2 - HIV associated neurocognitive disorders (HAND) are a group of neurological deficits that affect approximately half of people living with HIV (PLWH) despite effective antiretroviral therapy (ART). There are currently no reliable molecular biomarkers or treatments for HAND. Given the national opioid epidemic, as well as illegal and prescription use of opioid drugs among PLWH, it is critical to characterize the molecular interactions between HIV and opioids in cells of the CNS. It is also important to study the role of opioid substitution therapies in the context of HIV and CNS damage in vitro and in vivo. A major mechanism contributing to HIV neuropathogenesis is chronic, low-level inflammation in the CNS. HIV enters the brain within 4–8 days after peripheral infection and establishes CNS reservoirs, even in the context of ART, that are difficult to identify and eliminate. Infected cells, including monocytes, macrophages, and microglia, produce chemokines, cytokines, neurotoxic mediators, and viral proteins that contribute to chronic inflammation and ongoing neuronal damage. Opioids have been shown to impact these immune cells through a variety of molecular mechanisms, including opioid receptor binding and cross desensitization with chemokine receptors. The effects of opioid use on cognitive outcomes in individuals with HAND in clinical studies is variable, and thus multiple biological mechanisms are likely to contribute to the complex relationship between opioids and HIV in the CNS. In this review, we will examine what is known about both HIV and opioid mediated neuropathogenesis, and discuss key molecular processes that may be impacted by HIV and opioids in the context of neuroinflammation and CNS damage. We will also assess what is known about the effects of ART on these processes, and highlight areas of study that should be addressed in the context of ART.

AB - HIV associated neurocognitive disorders (HAND) are a group of neurological deficits that affect approximately half of people living with HIV (PLWH) despite effective antiretroviral therapy (ART). There are currently no reliable molecular biomarkers or treatments for HAND. Given the national opioid epidemic, as well as illegal and prescription use of opioid drugs among PLWH, it is critical to characterize the molecular interactions between HIV and opioids in cells of the CNS. It is also important to study the role of opioid substitution therapies in the context of HIV and CNS damage in vitro and in vivo. A major mechanism contributing to HIV neuropathogenesis is chronic, low-level inflammation in the CNS. HIV enters the brain within 4–8 days after peripheral infection and establishes CNS reservoirs, even in the context of ART, that are difficult to identify and eliminate. Infected cells, including monocytes, macrophages, and microglia, produce chemokines, cytokines, neurotoxic mediators, and viral proteins that contribute to chronic inflammation and ongoing neuronal damage. Opioids have been shown to impact these immune cells through a variety of molecular mechanisms, including opioid receptor binding and cross desensitization with chemokine receptors. The effects of opioid use on cognitive outcomes in individuals with HAND in clinical studies is variable, and thus multiple biological mechanisms are likely to contribute to the complex relationship between opioids and HIV in the CNS. In this review, we will examine what is known about both HIV and opioid mediated neuropathogenesis, and discuss key molecular processes that may be impacted by HIV and opioids in the context of neuroinflammation and CNS damage. We will also assess what is known about the effects of ART on these processes, and highlight areas of study that should be addressed in the context of ART.

KW - buprenorphine

KW - central nervous system

KW - HIV-associated neurocognitive disorders

KW - macrophages

KW - monocytes

KW - next generation sequencing

KW - substance abuse

UR - http://www.scopus.com/inward/record.url?scp=85074423414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074423414&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.02445

DO - 10.3389/fimmu.2019.02445

M3 - Review article

C2 - 31681322

AN - SCOPUS:85074423414

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 2445

ER -